Get started
Author

Bernardo Herrera‐Imbroda

Observed names: B Herrera-Imbroda, B. Herrera Imbroda, B. Herrera-Imbroda, Bernardo B. Herrera Imbroda, Bernardo HERRERA-IMBRODA, Bernardo Herrera, Bernardo Herrera Imbroda, Bernardo Herrera-Imbroda, Herrera-Imbroda Bernardo
Observed institutions: Spanish National Cancer Research Centre, Hospital Regional Universitario de Málaga, Andalusian Centre for Nanomedicine and Biotechnology, Hospital Clínico Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga
ORCID: 0000-0002-6235-4897
Observed ORCID: 0000-0002-6235-4897
OpenAlex ID: A5020143977
The Urinary Tract Microbiome in Health and Disease
2016 · Isabel M. Aragón, Bernardo Herrera-Imbroda, et al. · European Urology Focus · 326
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial
2024 · Fred Saad, Egils Vjaters, et al. · Journal of Clinical Oncology · 193
Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes
2024 · D. Olmos, D. Lorente, et al. · Annals of Oncology · 98
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial
2025 · Maria De Santis, Joan Palou Redorta, et al. · The Lancet · 95
Cell Therapy for Stress Urinary Incontinence
2015 · Melanie L. Hart, Ander Izeta, et al. · Tissue Engineering Part B Reviews · 63
Anesthesia in Combination with Propofol Increases Disease-Free Survival in Bladder Cancer Patients Who Undergo Radical Tumor Cystectomy as Compared to Inhalational Anesthetics and Opiate-Based Analgesia
2020 · Jose Luis Guerrero Orriach, Aida Raigon Ponferrada, et al. · Oncology · 52
Stress urinary incontinence animal models as a tool to study cell-based regenerative therapies targeting the urethral sphincter
2014 · Bernardo Herrera-Imbroda, María F. Lara, et al. · Advanced Drug Delivery Reviews · 50
Cell Therapy Clinical Trials for Stress Urinary Incontinence: Current Status and Perspectives
2018 · Isabel María Aragón, Bernardo Herrera Imbroda, et al. · International Journal of Medical Sciences · 47
Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)
2018 · Nuria Romero-Laorden, Rebeca Lozano, et al. · British Journal of Cancer · 45
BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes
2025 · D. Olmos, D. Lorente, et al. · Annals of Oncology · 36
PDF
Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance
2018 · Ángel Borque-Fernando, José Rubio-Briones, et al. · Prostate Cancer and Prostatic Diseases · 36
EPMA-World Congress 2015
2016 · EFLM, Jella-Andrea Abraham, et al. · The EPMA Journal · 36
PDF
Percutaneous Tibial Nerve Stimulation in Treatment of Overactive Bladder: When Should Retreatment Be Started?
2011 · Cristobal Marchal, Bernardo Herrera, et al. · Urology · 36
Percutaneous Tibial Nerve Stimulation Therapy for Overactive Bladder Syndrome: Clinical Effectiveness, Urodynamic, and Durability Evaluation
2017 · Sergío Del Río-Gonzalez, Isabel M. Aragon, et al. · Urology · 31
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial
2025 · Andrea Necchi, Félix Guerrero-Ramos, et al. · The Lancet Oncology · 24
New Perspectives on the Role of Liquid Biopsy in Bladder Cancer: Applicability to Precision Medicine
2024 · Fernardo Alberca-del Arco, Daniel Prieto-Cuadra, et al. · Cancers · 24
PDF
Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort
2021 · Friederike Kullmann, Pamela L Strissel, et al. · Journal of Clinical Pathology · 22
PDF
Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first-line (1L) treatment stratified by BRCA status.
2023 · David Olmos, David Lorente, et al. · Journal of Clinical Oncology · 20
Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial
2016 · Nicolás Roberto Robles, Ramón Peces, et al. · Orphanet Journal of Rare Diseases · 20
PDF
The use of botulinum toxin in benign prostatic hyperplasia
2011 · Cristobal Marchal, Juan E. Perez, et al. · Neurourology and Urodynamics · 19
A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)
2024 · Bertrand F. Tombal, Francisco Gomez-Veiga, et al. · European Urology Oncology · 18
PDF
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study
2023 · Nuria Romero-Laorden, David Lorente, et al. · European Urology Oncology · 18
Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial
2024 · Alonso Garcia-Ruiz, Carlos Macarro, et al. · European Urology · 17
PDE5A Polymorphisms Influence on Sildenafil Treatment Success
2016 · Cristobal Marchal-Escalona, Bernardo Herrera-Imbroda, et al. · The Journal of Sexual Medicine · 16
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results
2025 · Andrea Necchi, Félix Guerrero-Ramos, et al. · Journal of Clinical Oncology · 14
Works count: 82
Citation count: 1,497
H-index: 20
I10-index: 31
Year
Topic
Type